Growth characteristics in vitro of myeloid leukaemic cells with t(6;9)

Leukemia & Lymphoma
P E HollingsP H Fitzgerald

Abstract

We report an analysis of in vitro growth characteristics of leukaemic cells from five patients with t(6;9)(p23;q34). Consistent with other reports of this abnormality, our patients were comparatively young (median age at diagnosis, 29 years), and responded poorly to conventional treatment (median survival from diagnosis, 10 months). During active disease the CFU-GM growth patterns were characterized by an abundance of granulocytic aggregates (mostly 20-100 cells in size) whose leukaemic origin was confirmed by cytogenetic analysis. During remission induction, colonies derived from regenerating normal progenitor cell colonies could be distinguished from those derived from persisting leukaemic cells on the basis of differences in size, morphology, in situ staining characteristics, and karyotype. Remission growth patterns were those of a normal bone marrow. Our findings add to a growing recognition that the t(6;9) identifies a subset of leukaemic patients with distinctive clinical, haematologic, molecular, and in vitro growth characteristics for whom conventional treatment offers little hope of cure or long survival.

References

Oct 1, 1992·Baillière's Clinical Haematology·M von LindernG Grosveld
Jul 15, 1989·Cancer Genetics and Cytogenetics·D C ArthurG W Dewald
Oct 1, 1988·AIDS·S M BurnsR P Brettle
Apr 1, 1988·Cancer Genetics and Cytogenetics·P E HollingsP H Fitzgerald
Jan 1, 1987·Leukemia Research·P E Hollings, P H Fitzgerald
Apr 1, 1985·American Journal of Hematology·M G PearsonE L Prigogina
Oct 30, 1971·Lancet·M Seabright
Feb 1, 1983·Cancer Genetics and Cytogenetics·L M Webber, O M Garson
Apr 1, 1984·Scandinavian Journal of Haematology·A GustavssonI Olsson
Feb 1, 1983·American Journal of Hematology·C M Richman, J D Rowley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.